QIAGEN Introduces QIAsymphony RGQ(R), a Novel Automated System for all Molecular Testing Needs

By Qiagen, PRNE
Tuesday, August 31, 2010

Automated Workflow With Broadest Available PCR-Based Molecular Diagnostic Assay Menu(1)

VENLO, The Netherlands, September 1, 2010 - QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced
the launch of its highly flexible automated solution QIAsymphony RGQ(R). This
novel, integrated system sets new standards for molecular testing and
incorporates all workflow steps from sample to detection. QIAsymphony offers
many features which create exceptional flexibility, such as continuous
loading, random access, open channels for user-developed tests, the broadest
menu of commercial assays as well as the ability to process an almost
unlimited range of sample types. QIAsymphony thus provides laboratories with
a system that transforms their work in the emerging field of molecular

This new and complete workflow solution is comprised of modules that can
be used as stand-alone systems or combined into a fully integrated system.
The QIAsymphony RGQ system comprises the physical and data integration of the
modules QIAsymphony SP for sample preparation, QIAsymphony AS for assay
setup, and the Rotor-Gene(R) Q real time PCR thermocycler. QIAsymphony also
provides the broadest available PCR-based assay menu, including the artus(TM)
real time PCR kits for the detection of HIV, HCV, HBV, and a transplantation
panel with CMV, EBV, HSV, VZV and BKV(1). A large pipeline of further tests
will be launched in the coming months, including therascreen(R) EGFR, KRAS,
as well as artus Influenza, CT, CT/Ng and an extended transplantation panel
(1). Many more tests are in development as well as the ability to integrate
detection options such as pyrosequencing, and multiplexing solutions.

Dr. Mark Wasner, at the MVZ fur Mikrobiologie, Labordiagnostik und
Hygiene Dessau GmbH, a private medical laboratory in Dessau, Germany, is
among the first users of the novel QIAsymphony RGQ. "The advantage of the
QIAsymphony RGQ is the broad spectrum of applications for medical
laboratories, such as the option to combine in-house and IVD applications,"
said Dr. Wasner.

The complete CE-IVD-compliant workflow of the standardized system enables
reliable pathogen detection with the flexibility to process multiple input
formats and a varying number of 1-72 samples per run. The QIAsymphony RGQ
also offers workflow optimization through the option for parallel runs and
flexible batch sizes and intuitive, easy-to-use software.

"Our new integrated and validated QIAsymphony RGQ system has been
developed to meet the testing needs of molecular diagnostic laboratories now
and in the future", said Peer Schatz, QIAGEN's Chief Executive Officer.
"Following the launch, QIAGEN will continue to expand the menu and the
features of the QIAsymphony series and customers can expect very powerful
additions in respect to sample input and processing, instrument performance
and continuous expansion of the exceptional instrument testing panel that is
available already today."

Find out more about the QIAsymphony RGQ including a video on
the European websites at www.qiagen.com/mc/QIAsymphonyRGQ. For a
high resolution image please contact us at marc.egelhofer@qiagen.com.


QIAGEN N.V., a Netherlands holding company, is the leading
global provider of sample and assay technologies. Sample technologies are
used to isolate and process DNA, RNA and proteins from biological samples
such as blood or tissue. Assay technologies are used to make such isolated
bio-molecules visible. QIAGEN has developed and markets more than 500 sample
and assay products as well as automated solutions for such consumables. The
company provides its products to molecular diagnostics laboratories, academic
researchers, pharmaceutical and biotechnology companies, and applied testing
customers for purposes such as forensics, animal or food testing and
pharmaceutical process control. QIAGEN's assay technologies include one of
the broadest panels of molecular diagnostic tests available worldwide. This
panel includes the digene HPV Test, which is regarded as a "gold standard" in
testing for high-risk types of human papillomavirus (HPV), the primary cause
of cervical cancer, as well as a broad suite of solutions for infectious
disease testing and companion diagnostics. QIAGEN employs more than 3,500
people in over 30 locations worldwide. Further information about QIAGEN can
be found at www.qiagen.com/.

1 - Test kits and the RGQ instrument are not currently
available in the US for in-vitro diagnostic use. Consult your local QIAGEN
representative to determine availability of the various test kits in your
country for in vitro diagnostic use.


    Dr Marc Egelhofer
    e-mail: marc.egelhofer@qiagen.com

    Cassie Knapp
    e-mail: cassie.knapp@qiagen.com

Contact: Global: Dr Marc Egelhofer, QIAGEN GmbH, +49-2103-29-11741, e-mail: marc.egelhofer at qiagen.com; US: Cassie Knapp, QIAGEN GmbH, +1-240-686-7686, e-mail: cassie.knapp at qiagen.com

Clinical Trials / Medical Discoveries News

The Netherlands News

will not be displayed